MBP (85-99) peptide antagonist trifluoroacetate salt

MBP (85-99) peptide antagonist, or J5, is a 15 amino acid peptide fragment designed on the binding motif of MBP 85-99 (myelin basic protein 85-99) to HLA-DR2 (human leukocyte antigen-DR2), which competes with and inhibits the binding of MBP (85-99) to HLA-DR2 and IL-2. MBP 85-99 is the the immunodominant epitope of MBP and a major candidate autoantigen in multiple sclerosis (MS), making this peptide a useful tool for MS research. p>

MBP (85-99) peptide antagonist inhibits binding of MBP 85-99 to HLA-DR2 and IL-2; tool for MS research. MBP (85-99) peptide antagonist inhibits the binding of MBP 85-99 to HLA-DR2 and IL-2 and is a tool for MS research. The peptide antagonist is a 15-mer peptide that competes with Myelin Basic Protein MBP (85-99), the immunodominant epitope of MBP and major candidate autoantigen in multiple sclerosis (MS).

[1] CASSANDRA E SMITH. Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005: 9595-9600. DOI:10.1073/pnas.0504131102.
[2] JOEL N H STERN. Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102 5: 1620-1625. DOI:10.1073/pnas.0409022102.
[3] FRIDKIS-HARELI M. Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.[J]. Clinical & Developmental Immunology, 2013, 2013: 826191. DOI:10.1155/2013/826191.